Litcius/Paper detail

Enhanced Osteosarcoma Immunotherapy via CaCO<sub>3</sub> Nanoparticles: Remodeling Tumor Acidic and Immune Microenvironment for Photodynamic Therapy

Y J Gao, Zhuoying Wang, Xinmeng Jin, Xiaoli Wang, Yining Tao, Shandeng Huang, Yun Wang, Yingqi Hua, Xuran Guo, Jing Xu, Zhengdong Cai

2024Advanced Healthcare Materials21 citationsDOIOpen Access PDF

Abstract

Abstract Osteosarcoma (OS) is a “cold” tumor enriched in noninflammatory M2 phenotype tumor‐associated macrophages (TAMs), which limits the efficacy of immunotherapy. The acidic tumor microenvironment (TME), generated by factors such as excess hydrogen (H + ) ions and high lactate levels, activates immunosuppressive cells, further promoting a suppressive tumor immune microenvironment (TIME). Therefore, a multitarget synergistic combination strategy that neutralizes the acidic TME and reprograms TAMs can be beneficial for OS therapy. Here, a calcium carbonate (CaCO 3 )/polydopamine (PDA)‐based nanosystem (A‐NPs@(SHK+Ce6)) is developed. CaCO 3 nanoparticles are used to neutralize H + ions and alleviate the suppressive TIME, and the loaded SHK not only synergizes with photodynamic therapy (PDT) but also inhibits lactate production, further reversing the acidic TME and repolarizing TAMs to consequently lead to enhanced PDT‐induced tumor suppression and comprehensive beneficial effects on antitumor immune responses. Importantly, A‐NPs@(SHK+Ce6), in combination with programmed cell death protein 1 (PD‐1) checkpoint blockade, shows a remarkable ability to eliminate distant tumors and promote long‐term immune memory function to protect against rechallenged tumors. This work presents a novel multiple‐component combination strategy that coregulates the acidic TME and TAM polarization to reprogram the TIME.

Topics & Concepts

Tumor microenvironmentCancer researchImmune systemPhotodynamic therapyImmunotherapyChemistryCancer immunotherapyCD8PhotosensitizerMedicineImmunologyOrganic chemistryNanoplatforms for cancer theranosticsCancer, Hypoxia, and MetabolismImmune cells in cancer